Pfizer's Prevnar, Sanofi-Aventis' ActHIB Vaccines Temporarily Suspended In Japan; Safety Committee Unwilling To Lift Action After First Meeting
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Japan's Ministry of Health, Labor and Welfare temporarily suspended Pfizer Inc.'s Prevnar and Sanofi-Aventis SA's ActHIB following the death of four infants and now the companies find themselves in front of Japan's cautious safety council awaiting a decision that has the potential to have a large commercial impact, particularly on the blockbuster Prevnar, the latest iteration of which - Prevnar 13, a 13-valent vaccine for both children and adults - is currently in Phase III trials in Japan
You may also be interested in...
Japan Clears Merck's Gardasil To Ease HPV Vaccine Shortage; AstraZeneca, Astellas Also Gain Approvals
July kicks off a good start for the Japanese subsidiary of Merck & Co. Inc., known as Merck, Sharp & Dohme, with three new drug approvals from Japan's Ministry of Health, Labor and Welfare. Among them, cervical cancer vaccine Gardasil will largely benefit from a recently expanded Japanese government public coverage program for human papillomavirus vaccines
Japan Clears Merck's Gardasil To Ease HPV Vaccine Shortage; AstraZeneca, Astellas Also Gain Approvals
July kicks off a good start for the Japanese subsidiary of Merck & Co. Inc., known as Merck, Sharp & Dohme, with three new drug approvals from Japan's Ministry of Health, Labor and Welfare. Among them, cervical cancer vaccine Gardasil will largely benefit from a recently expanded Japanese government public coverage program for human papillomavirus vaccines
Japan Pushing For Vaccine Advisory Committee To Address Drug Lag - PhRMA Symposium
TOKYO - The drug lag in Japan includes a substantial vaccine lag, which is amplified by the lack of a command center to draw up Japan's vaccination policies, plans and programs like U.S. FDA's Advisory Committee on Immunization Practices and the UK's Joint Committee on Vaccination and Immunization. Now, an official from the Ministry of Health Labor and Welfare's Office of Vaccination Policy Reform suggests the agency adopt a similar committee